PT  - JOURNAL ARTICLE
AU  - Daisy Yan
AU  - Robert Borucki
AU  - Richard D Sontheimer
AU  - Victoria P Werth
TI  - Candidate drug replacements for quinacrine in cutaneous lupus erythematosus
AID  - 10.1136/lupus-2020-000430
DP  - 2020 Oct 01
TA  - Lupus Science & Medicine
PG  - e000430
VI  - 7
IP  - 1
4099  - http://lupus.bmj.com/content/7/1/e000430.short
4100  - http://lupus.bmj.com/content/7/1/e000430.full
SO  - Lupus Sci Med2020 Oct 01; 7
AB  - Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.